


CLAIMS

1. A compound having the formula I



(I)

wherein

X is N or CH;

10 Y is NR_2CH_2 , CH_2NR_2 , NR_2CO , CONR_2 or NR_2SO_2

wherein R_2 is H or $\text{C}_1\text{-C}_6$ alkyl;

R_1 is H, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_6$ cycloalkyl;

R_3 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl or $(\text{CH}_2)_n\text{-aryl}$,

wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected
15 from N, O and S and which may be mono- or di-substituted with R_4 and/or R_5 ;

wherein R_4 is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, halogen, CN, CF_3 , OH,

$\text{C}_1\text{-C}_6$ alkoxy, NR_6R_7 , OCF_3 , SO_3CH_3 , SO_3CF_3 , $\text{SO}_2\text{NR}_6\text{R}_7$, phenyl, phenyl-
 $\text{C}_1\text{-C}_6$ alkyl, phenoxy, $\text{C}_1\text{-C}_6$ alkylphenyl, an optionally substituted heterocyclic
ring containing one or two heteroatoms selected from N, O, S, SO and SO_2

20 wherein the substituent(s) is(are) selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl and
phenyl- $\text{C}_1\text{-C}_6$ alkyl, an optionally substituted heteroaromatic ring containing one
or two heteroatoms selected from N, O and S wherein the substituent(s) is(are)
selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl and phenyl- $\text{C}_1\text{-C}_6$ alkyl, or COR_8 ;

wherein R_6 is H, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_6$ cycloalkyl;

R₇ is H, C₁-C₆ alkyl or C₃-C₆ cycloalkyl; and

R₈ is C₁-C₆ alkyl, C₃-C₆ cycloalkyl, CF₃, NR₆R₇, phenyl, a heteroaromatic ring containing one or two heteroatoms selected from N, O and S or a heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO₂;

wherein R₅ is H, OH, CF₃, OCF₃, halogen, C₁-C₆ alkyl or C₁-C₆ alkoxy;

n is 0-4;

R₉ is H, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, OCF₃, OCHF₂, OCH₂F, halogen, CN, CF₃, OH, C₁-C₆ alkoxy, C₁-C₆ alkoxy-C₁-C₆ alkyl, NR₆R₇, SO₃CH₃, SO₃CF₃, SO₂NR₆R₇, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N, O and S, wherein the substituent(s) is(are) C₁-C₆ alkyl; or COR₈; wherein R₆, R₇ and R₈ are as defined above,

as (*R*)-enantiomers, (*S*)-enantiomers or a racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein Y is NR₂CO or CONR₂.

3. A compound according to any one of claims 1-2 wherein X is N.

4. A compound according to any one of claims 1-3 wherein R₁ is H or C₁-C₆ alkyl.

5. A compound according to any one of claims 1-4 wherein R₃ is (CH₂)_n-aryl.

6. A compound according to any one of claims 1-4 wherein R₃ is (CH₂)_n-aryl which is substituted with R₄, which is an optionally substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N, O and S, or COR₈.

7. A compound according to any one of claims 5 and 6 wherein n is 0.
8. A compound according to claim 6 wherein R_8 is NR_6R_7 or a heterocyclic ring
5 containing two heteroatoms selected from N and O.
9. A compound according to any one of claims 1-8 wherein R_9 is H, C_1 - C_6 alkyl, $OCHF_2$, halogen or C_1 - C_6 alkoxy.
10. 10. A compound according to any one of claims 1- 9 wherein X is N, Y is NR_2CO and R_9 is C_1 - C_6 alkoxy.
11. A compound according to claim 10 wherein X is N, Y is NR_2CO , R_4 is morpholino or COR_8 and R_9 is C_1 - C_6 alkoxy.
- 15 12. A compound according to any one of claims 1- 9 wherein X is N, Y is NR_2CO and R_9 is C_1 - C_6 alkyl.
13. A compound according to claim 12 wherein X is N, Y is NR_2CO , R_4 is morpholino or
20 COR_8 and R_9 is C_1 - C_6 alkyl.
14. A compound according to any one of claims 1- 9 wherein X is N, Y is NR_2CO and R_9 is H.
- 25 15. A compound according to claim 14 wherein X is N, Y is NR_2CO , R_4 is morpholino or COR_8 and R_9 is H.
16. A compound which is 4-(4-methylpiperazin-1-yl)-N-(4-morpholinophenyl)indan-2-carboxamide in the form of a free base or a pharmaceutically acceptable salt or solvate
30 thereof.

17. A pharmaceutical formulation comprising as active ingredient a therapeutically effective amount of the compound of any one of claims 1-16 as an enantiomer or racemate in the form of a free base or a pharmaceutically acceptable salt or solvate thereof optionally
5 in association with diluents, excipients or inert carriers.

18. A pharmaceutical formulation according to claim 17 for use in the treatment of 5-hydroxytryptamine mediated disorders.

10 19. A pharmaceutical formulation according to any one of claims 17 or 18 for use in the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease,
15 thermoregulatory disorders, pain, hypertension, urinary incontinence or vasospasm; or for growth control of tumors.

20. A compound as defined in any of claims 1-16 for use in therapy.

20 21 A compound as defined in claim 20 for use in the treatment of disorders in the central nervous system.

22. A compound as defined in claim 21 for use in the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual
25 disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.

23. A compound as defined in claim 22 for use in the treatment of urinary incontinence or
30 vasospasm or for growth control of tumors.

24. A compound as defined in claim 20 for use in the treatment of 5-hydroxytryptamine mediated disorders.
- 5 25. A compound as defined in claim 24 for use as a h5-HT_{1B} antagonist.
26. The use of a compound defined in any of claims 1-16 in the manufacture of a medicament for the treatment of disorders in the central nervous system and/or urinary incontinence or vasospasm; or for growth control of tumors.
- 10 27. The use according to claim 26 in the manufacture of a medicament for the treatment of mood disorders, anxiety disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression,
- 15 schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.
28. The use of a compound defined in any of claims 1-16 in the manufacture of a medicament for the treatment of 5-hydroxytryptamine mediated disorders.
- 20 29. The use according to claim 28 wherein the compound according to any one of claims 1-16 is used as a h5-HT_{1B} antagonist.
30. A method for the treatment of disorders in the central nervous system and/or urinary
- 25 incontinence or vasospasm or for growth control of tumors by administering to a mammal including man in need of such a treatment a therapeutically effective amount of a compound defined in any of claims 1-16.
31. A method according to claim 30 for the treatment of mood disorders, anxiety
- 30 disorders, personality disorders, obesity, anorexia, bulimia, premenstrual syndrome, sexual


disturbances, alcoholism, tobacco abuse, autism, attention deficit, hyperactivity disorder, migraine, memory disorders, pathological aggression, schizophrenia, endocrine disorders, stroke, dyskinesia, Parkinson's disease, thermoregulatory disorders, pain or hypertension.

5 32. A method for the treatment of 5-hydroxytryptamine mediated disorders by administering to a mammal including man in need of such a treatment a therapeutically effective amount of a compound defined in any of claims 1-16.

33 A method according to claim 32 wherein the compound according to any one of claims
10 1-16 is used as a h5-HT_{1B} antagonist.


34. A process for the preparation of the compound of formula I according to claim 1 by reacting, in the case where Y is CONR₂, R₁, R₂, R₃ and R₉ is as defined in general
formula I in claim 1, a compound of formula A

15



20 with a compound of formula VII, wherein X is a leaving group.

35. A compound having the formula



wherein

5 Y is CONR_2 wherein R_2 is H or $\text{C}_1\text{-C}_6$ alkyl

R_3 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl or $(\text{CH}_2)_n\text{-aryl}$,

wherein aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted with R_4 and/or R_5 ;

10 wherein R_4 is H, $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, halogen, CN, CF_3 , OH, $\text{C}_1\text{-C}_6$ alkoxy, NR_6R_7 , OCF_3 , SO_3CH_3 , SO_3CF_3 , $\text{SO}_2\text{NR}_6\text{R}_7$, phenyl, phenyl- $\text{C}_1\text{-C}_6$ alkyl, phenoxy, $\text{C}_1\text{-C}_6$ alkylphenyl, an optionally substituted heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO_2 wherein the substituent(s) is(are) selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl and phenyl- $\text{C}_1\text{-C}_6$ alkyl, an optionally substituted
15 heteroaromatic ring containing one or two heteroatoms selected from N, O and S wherein the substituent(s) is(are) selected from $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl and phenyl- $\text{C}_1\text{-C}_6$ alkyl, or COR_8 ;

wherein R_6 is H, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_6$ cycloalkyl;

20 R_7 is H, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_3\text{-C}_6$ cycloalkyl; and

R_8 is $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, CF_3 , NR_6R_7 , phenyl, a

heteroaromatic ring containing one or two heteroatoms selected from N, O and S or a heterocyclic ring containing one or two heteroatoms selected from N, O, S, SO and SO_2 wherein R_6 and R_7 are as defined
25 above;

wherein R_5 is H, OH, CF_3 , OCF_3 , halogen, C_1 - C_6 alkyl or C_1 - C_6 alkoxy;

n is 0-4;

and

- 5 R_9 is H, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, OCF_3 , $OCHF_2$, OCH_2F , halogen, CN, CF_3 , OH, C_1 - C_6 alkoxy, C_1 - C_6 alkoxy- C_1 - C_6 alkyl, NR_6R_7 , SO_3CH_3 , SO_3CF_3 , $SO_2NR_6R_7$, an unsubstituted or substituted heterocyclic or heteroaromatic ring containing one or two heteroatoms selected from N and O, wherein the substituent(s) is(are) C_1 - C_6 alkyl; or COR_8 ; wherein R_6 , R_7 and R_8 are as defined above.